ES2167716T3 - Alquil-4-silil-fenoles y esteres de los mismos como agentes antiescleroticos. - Google Patents

Alquil-4-silil-fenoles y esteres de los mismos como agentes antiescleroticos.

Info

Publication number
ES2167716T3
ES2167716T3 ES97907998T ES97907998T ES2167716T3 ES 2167716 T3 ES2167716 T3 ES 2167716T3 ES 97907998 T ES97907998 T ES 97907998T ES 97907998 T ES97907998 T ES 97907998T ES 2167716 T3 ES2167716 T3 ES 2167716T3
Authority
ES
Spain
Prior art keywords
rent
independently
hydrogen
inhibit
res
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907998T
Other languages
English (en)
Spanish (es)
Inventor
Steven J Busch
Kim S Chen
Michael J Edwards
James E Matt Jr
Roger A Parker
Mark J Vaal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2167716T3 publication Critical patent/ES2167716T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES97907998T 1996-04-30 1997-03-03 Alquil-4-silil-fenoles y esteres de los mismos como agentes antiescleroticos. Expired - Lifetime ES2167716T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/637,968 US5608095A (en) 1996-04-30 1996-04-30 Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents

Publications (1)

Publication Number Publication Date
ES2167716T3 true ES2167716T3 (es) 2002-05-16

Family

ID=24558107

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907998T Expired - Lifetime ES2167716T3 (es) 1996-04-30 1997-03-03 Alquil-4-silil-fenoles y esteres de los mismos como agentes antiescleroticos.

Country Status (19)

Country Link
US (1) US5608095A (enExample)
EP (1) EP0900225B1 (enExample)
JP (1) JP4309473B2 (enExample)
KR (1) KR100503181B1 (enExample)
CN (1) CN1216993A (enExample)
AR (1) AR006890A1 (enExample)
AT (1) ATE212639T1 (enExample)
AU (1) AU711322B2 (enExample)
BR (1) BR9709190A (enExample)
CA (1) CA2251991C (enExample)
DE (1) DE69710191T2 (enExample)
DK (1) DK0900225T3 (enExample)
ES (1) ES2167716T3 (enExample)
IL (1) IL126758A0 (enExample)
NO (1) NO985039L (enExample)
PT (1) PT900225E (enExample)
TW (1) TW474940B (enExample)
WO (1) WO1997041129A1 (enExample)
ZA (1) ZA973503B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
WO1997040837A1 (en) * 1996-04-30 1997-11-06 Hoechst Marion Roussel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2,6-di-alkyl-4-silyl-phenols
CN1287783C (zh) * 1997-05-14 2006-12-06 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
CA2295232A1 (en) * 1997-06-25 1998-12-30 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[ (dimethyl-4-methoxyphenylsilyl) -methyloxy]phenol and 2,6-di-t-butyl-4-[ (dimethyl-2-methoxy-phenylsilyl) -methyloxy]phenol
CA2294247C (en) * 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
CN1332849A (zh) * 1998-11-09 2002-01-23 埃瑟若詹尼克斯公司 降低血浆胆固醇水平的方法和组合物
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
CN100512809C (zh) * 2001-10-25 2009-07-15 阿特罗吉尼克斯公司 化合物在制备用于慢性移植排斥的药物中的用途
IL161741A0 (en) * 2001-11-09 2005-11-20 Atherogenics Inc Methods of reversing and preventingcardiovascular pathologies
BR0215240A (pt) * 2001-12-19 2004-10-26 Atherogenics Inc Derivados de calcona e seu uso no tratamento de doenças
US6960683B2 (en) * 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
WO2004062622A2 (en) * 2003-01-13 2004-07-29 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2004108094A2 (en) * 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005039596A1 (en) * 2003-10-17 2005-05-06 Amylin Pharmaceuticals, Inc. Silyl phenols for promoting vascular health
US7294737B2 (en) 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
CA2571589A1 (en) * 2004-07-01 2006-01-19 Atherogenics, Inc. Compounds and methods for treating diabetic vascular diseases
CA2682258A1 (en) * 2007-03-26 2008-10-02 Salutria Pharmaceuticals Llc Methods and compositions of derivatives of probucol for the treatment of diabetes
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
EP2558433B1 (en) * 2010-04-15 2014-06-18 Merck Patent GmbH Process for the preparation of hydroquinones
CN109641004A (zh) 2016-07-08 2019-04-16 燕财成有限公司 实体癌治疗剂

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129262A (en) * 1962-10-08 1964-04-14 Consolidation Coal Co Reduction of organic thiocyanates
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
US3897500A (en) * 1971-12-10 1975-07-29 Continental Oil Co Alkylidenedithiobisphenols
US3786100A (en) * 1971-12-10 1974-01-15 Continental Oil Co Keto substituted alkylidenedithiobisphenols
JPS61263988A (ja) * 1985-05-16 1986-11-21 Shionogi & Co Ltd シリル置換エ−テル類および殺虫・殺ダニ剤
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US4719237A (en) * 1986-01-28 1988-01-12 Merrell Dow Pharmaceuticals Inc. Cardiac antiarrythmic method employing probucol
US4734527A (en) * 1986-10-17 1988-03-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol
US4861443A (en) * 1987-01-14 1989-08-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) by electrocatalysis
US4772363A (en) * 1987-01-14 1988-09-20 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol by electrocatalysis
US5401883A (en) * 1987-01-20 1995-03-28 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol and 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol)
US4975467A (en) * 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
JPH0813824B2 (ja) * 1988-10-27 1996-02-14 北興化学工業株式会社 有機ケイ素化合物
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US5047555A (en) * 1988-12-13 1991-09-10 Tanabe Seiyaku Co., Ltd. 4-aminophenol derivatives and processes for preparing the same
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5008421A (en) * 1989-07-05 1991-04-16 Aristech Chemical Corporation Silyl derivatives of 2,6-dimethyl-4-allyl phenol
DE3935638A1 (de) * 1989-10-26 1991-05-02 Consortium Elektrochem Ind Organosilylalkylaromaten
US5061734A (en) * 1990-05-09 1991-10-29 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5112870A (en) * 1990-05-09 1992-05-12 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
JP2899064B2 (ja) * 1990-05-23 1999-06-02 キヤノン株式会社 液晶性化合物、これを含む液晶組成物およびこれを使用した液晶素子
NZ238807A (en) * 1990-07-05 1994-03-25 Merrell Dow Pharma Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5304668A (en) * 1990-07-05 1994-04-19 Merrell Dow Pharmaceuticals Bis-[4-(2,6-di-alkyl)phenolisilane derivatives as antiatherosclerotic agents
US5254549A (en) * 1991-12-19 1993-10-19 Merz & Co. Gmbh & Co. New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
ATE231915T1 (de) * 1992-09-02 2003-02-15 Isis Pharmaceuticals Inc Beeinflussing der zelladhäsie durch oligonukleotide
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
CA2148712C (en) * 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripheralization of hematopoietic stem cells
WO1994014786A1 (en) * 1992-12-22 1994-07-07 Smithkline Beecham Plc Piperidine derivatives as calcium channel antagonists
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
AU7559894A (en) * 1993-08-05 1995-02-28 Isis Pharmaceuticals, Inc. Oligomers for modulating metabolic function
JP3650144B2 (ja) * 1994-06-08 2005-05-18 花王株式会社 細胞接着抑制剤

Also Published As

Publication number Publication date
TW474940B (en) 2002-02-01
JP2001509782A (ja) 2001-07-24
AU711322B2 (en) 1999-10-14
KR100503181B1 (ko) 2006-03-03
CA2251991A1 (en) 1997-11-06
NO985039D0 (no) 1998-10-29
EP0900225A1 (en) 1999-03-10
EP0900225B1 (en) 2002-01-30
AU1985497A (en) 1997-11-19
DK0900225T3 (da) 2002-05-13
ATE212639T1 (de) 2002-02-15
JP4309473B2 (ja) 2009-08-05
AR006890A1 (es) 1999-09-29
WO1997041129A1 (en) 1997-11-06
ZA973503B (en) 1997-10-30
DE69710191D1 (de) 2002-03-14
NO985039L (no) 1998-12-21
CA2251991C (en) 2002-05-14
CN1216993A (zh) 1999-05-19
IL126758A0 (en) 1999-08-17
KR20000065101A (ko) 2000-11-06
BR9709190A (pt) 1999-08-10
US5608095A (en) 1997-03-04
PT900225E (pt) 2002-06-28
DE69710191T2 (de) 2002-07-25

Similar Documents

Publication Publication Date Title
ES2167716T3 (es) Alquil-4-silil-fenoles y esteres de los mismos como agentes antiescleroticos.
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
CO4900068A1 (es) Piperazina di - n - sustituidas y piperidinas 1,4 -di- sustituidas utiles como antagonistas muscarinicos
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
ES2122916B1 (es) Esteres de acidos oximsulfonicos y su empleo como acidos sulfonicos latentes.
ES2116583T3 (es) Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.
AR007135A1 (es) Compuestos de benzofurano y benzopirano, formulaciones farmaceuticas que los contienen y metodos para preparar los compuestos y las formulaciones
ES2094795T3 (es) Ftalocianinas polisustituidas.
PE121199A1 (es) Agonistas de prostaglandinas
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
NO912630L (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler som antiarteriosklerotiske midler
ES2082114T3 (es) Cables de fibra optica y componentes de los mismos que contienen una mezcla homogenea de proteccion apropiada para proteger las fibras opticas del hidrogeno y mezcla homogenea de proteccion correspondiente.
CO5540391A2 (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibi dores de la fosfodiesterasa
ES2075672T3 (es) Amidinocompuestos, su fabricacion y uso como medicamento.
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
ES2117281T3 (es) Nuevos analogos de la vitamina d.
ES2114619T3 (es) Nuevos analogos de la vitamina d.
ES2169113T3 (es) Nuevos compuestos amido-triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2191828T3 (es) Fenoles y tiofenoles sustituidos utiles como agentes antioxidantes.
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2167010T3 (es) Polimeros hidrosolubles y su empleo en formulaciones cosmeticas.
ES2045126T3 (es) Agentes terapeuticos.
ES2036214T3 (es) Un procedimiento para la preparacion de compuestos de dihidropiridinas como agentes antialergicos y antiinflamatorios.
ES2087568T3 (es) Esteres aromaticos de fenilendialcanoatos como inhibidores de neutrofilo elastasa humana.